Abstract Purpose: Chromosomal microarray (CMA) testing provides the highest diagnostic yield for clinical testing of patients with developmental delay (DD), intellectual disability (ID), multiple ...

A large study from Children's Hospital Boston and the Boston-based Autism Consortium finds that a genetic test that samples the entire genome, known as chromosomal microarray analysis, has about ...

A genetic test known as chromosomal microarray analysis (CMA) could help identify the cause of sudden infant death syndrome (SIDS) or its counterpart in older children, known as sudden unexplained ...

Chromosomal microarray technology provides info on fetus Doctor: "It's an evolving technology" More insurers cover test, which costs about $1,500 WESTCHESTER, N. Y. -- A new test, called ...

The Autism Consortium says it has found chromosomal microarray analysis is the most effective genetic test for autism spectrum disorders.

Chromosomal microarray analysis, a two-year-old gene-chip technology used to look for potential genetic abnormalities in children, has proved to be remarkably sensitive in detecting abnormalities ...

Explore the booming Chromosomal Microarray Market, projected to grow from USD 1.69 Billion in 2025 to USD 3.32 Billion by 2034, at a 10.2% CAGR. Driven by demand for advanced genetic diagnostics ...

The test, called a chromosomal microarray, detected more irregularities that could result in genetic diseases — such as missing or repeated sections of genetic code — than did karyotyping ...

Sequenom, Inc. SQNM, a life sciences company providing innovative diagnostic testing and genetic analysis solutions, and CombiMatrix Corporation CBMX, a molecular diagnostics laboratory performing ...